-
Recommendations and guidelines from the ISMRM Diffusion Study Group for preclinical diffusion MRI: Part 2 -- Ex vivo imaging
Authors:
Kurt G Schilling,
Francesco Grussu,
Andrada Ianus,
Brian Hansen,
Rachel L C Barrett,
Manisha Aggarwal,
Stijn Michielse,
Fatima Nasrallah,
Warda Syeda,
Nian Wang,
Jelle Veraart,
Alard Roebroeck,
Andrew F Bagdasarian,
Cornelius Eichner,
Farshid Sepehrband,
Jan Zimmermann,
Lucas Soustelle,
Christien Bowman,
Benjamin C Tendler,
Andreea Hertanu,
Ben Jeurissen,
Lucio Frydman,
Yohan van de Looij,
David Hike,
Jeff F Dunn
, et al. (31 additional authors not shown)
Abstract:
The value of preclinical diffusion MRI (dMRI) is substantial. While dMRI enables in vivo non-invasive characterization of tissue, ex vivo dMRI is increasingly being used to probe tissue microstructure and brain connectivity. Ex vivo dMRI has several experimental advantages including higher signal-to-noise ratio and spatial resolution compared to in vivo studies, and more advanced diffusion contras…
▽ More
The value of preclinical diffusion MRI (dMRI) is substantial. While dMRI enables in vivo non-invasive characterization of tissue, ex vivo dMRI is increasingly being used to probe tissue microstructure and brain connectivity. Ex vivo dMRI has several experimental advantages including higher signal-to-noise ratio and spatial resolution compared to in vivo studies, and more advanced diffusion contrasts for improved microstructure and connectivity characterization. Another major advantage is direct comparison with histological data as a crucial methodological validation. However, there are a number of considerations that must be made when performing ex vivo experiments. The steps from tissue preparation, image acquisition and processing, and interpretation of results are complex, with many decisions that not only differ dramatically from in vivo imaging, but ultimately affect what questions can be answered using the data. This work represents 'Part 2' of a series of recommendations and considerations for preclinical dMRI, where we focus on best practices for dMRI of ex vivo tissue. We first describe the value that ex vivo imaging adds to the field of dMRI, followed by general considerations and foundational knowledge that must be considered when designing experiments. We then give guidelines for ex vivo protocols, including tissue preparation, imaging sequences and data processing including pre-processing, model-fitting, and tractography. Finally, we provide an online resource which lists publicly available ex vivo dMRI datasets and dedicated software packages. In each section, we attempt to provide guidelines and recommendations, but also highlight areas for which no guidelines exist, and where future work should lie. An overarching goal herein is to enhance the rigor and reproducibility of ex vivo dMRI acquisitions and analyses, and thereby advance biomedical knowledge.
△ Less
Submitted 7 February, 2023; v1 submitted 27 September, 2022;
originally announced September 2022.
-
Recommendations and guidelines from the ISMRM Diffusion Study Group for preclinical diffusion MRI: Part 1 -- In vivo small-animal imaging
Authors:
Ileana O Jelescu,
Francesco Grussu,
Andrada Ianus,
Brian Hansen,
Rachel L C Barrett,
Manisha Aggarwal,
Stijn Michielse,
Fatima Nasrallah,
Warda Syeda,
Nian Wang,
Jelle Veraart,
Alard Roebroeck,
Andrew F Bagdasarian,
Cornelius Eichner,
Farshid Sepehrband,
Jan Zimmermann,
Lucas Soustelle,
Christien Bowman,
Benjamin C Tendler,
Andreea Hertanu,
Ben Jeurissen,
Marleen Verhoye,
Lucio Frydman,
Yohan van de Looij,
David Hike
, et al. (32 additional authors not shown)
Abstract:
The value of in vivo preclinical diffusion MRI (dMRI) is substantial. Small-animal dMRI has been used for methodological development and validation, characterizing the biological basis of diffusion phenomena, and comparative anatomy. Many of the influential works in this field were first performed in small animals or ex vivo samples. The steps from animal setup and monitoring, to acquisition, anal…
▽ More
The value of in vivo preclinical diffusion MRI (dMRI) is substantial. Small-animal dMRI has been used for methodological development and validation, characterizing the biological basis of diffusion phenomena, and comparative anatomy. Many of the influential works in this field were first performed in small animals or ex vivo samples. The steps from animal setup and monitoring, to acquisition, analysis, and interpretation are complex, with many decisions that may ultimately affect what questions can be answered using the data. This work aims to serve as a reference, presenting selected recommendations and guidelines from the diffusion community, on best practices for preclinical dMRI of in vivo animals. In each section, we also highlight areas for which no guidelines exist (and why), and where future work should focus. We first describe the value that small animal imaging adds to the field of dMRI, followed by general considerations and foundational knowledge that must be considered when designing experiments. We briefly describe differences in animal species and disease models and discuss how they are appropriate for different studies. We then give guidelines for in vivo acquisition protocols, including decisions on hardware, animal preparation, imaging sequences and data processing, including pre-processing, model-fitting, and tractography. Finally, we provide an online resource which lists publicly available preclinical dMRI datasets and software packages, to promote responsible and reproducible research. An overarching goal herein is to enhance the rigor and reproducibility of small animal dMRI acquisitions and analyses, and thereby advance biomedical knowledge.
△ Less
Submitted 21 April, 2023; v1 submitted 26 September, 2022;
originally announced September 2022.
-
Can artificial intelligence (AI) be used to accurately detect tuberculosis (TB) from chest X-rays? An evaluation of five AI products for TB screening and triaging in a high TB burden setting
Authors:
Zhi Zhen Qin,
Shahriar Ahmed,
Mohammad Shahnewaz Sarker,
Kishor Paul,
Ahammad Shafiq Sikder Adel,
Tasneem Naheyan,
Rachael Barrett,
Sayera Banu,
Jacob Creswell
Abstract:
Artificial intelligence (AI) products can be trained to recognize tuberculosis (TB)-related abnormalities on chest radiographs. Various AI products are available commercially, yet there is lack of evidence on how their performance compared with each other and with radiologists. We evaluated five AI software products for screening and triaging TB using a large dataset that had not been used to trai…
▽ More
Artificial intelligence (AI) products can be trained to recognize tuberculosis (TB)-related abnormalities on chest radiographs. Various AI products are available commercially, yet there is lack of evidence on how their performance compared with each other and with radiologists. We evaluated five AI software products for screening and triaging TB using a large dataset that had not been used to train any commercial AI products. Individuals (>=15 years old) presenting to three TB screening centers in Dhaka, Bangladesh, were recruited consecutively. All CXR were read independently by a group of three Bangladeshi registered radiologists and five commercial AI products: CAD4TB (v7), InferReadDR (v2), Lunit INSIGHT CXR (v4.9.0), JF CXR-1 (v2), and qXR (v3). All five AI products significantly outperformed the Bangladeshi radiologists. The areas under the receiver operating characteristic curve are qXR: 90.81% (95% CI:90.33-91.29%), CAD4TB: 90.34% (95% CI:89.81-90.87), Lunit INSIGHT CXR: 88.61% (95% CI:88.03%-89.20%), InferReadDR: 84.90% (95% CI: 84.27-85.54%) and JF CXR-1: 84.89% (95% CI:84.26-85.53%). Only qXR met the TPP with 74.3% specificity at 90% sensitivity. Five AI algorithms can reduce the number of Xpert tests required by 50%, while maintaining a sensitivity above 90%. All AI algorithms performed worse among the older age and people with prior TB history. AI products can be highly accurate and useful screening and triage tools for TB detection in high burden regions and outperform human readers.
△ Less
Submitted 28 May, 2021; v1 submitted 9 June, 2020;
originally announced June 2020.
-
Investigating Active Learning and Meta-Learning for Iterative Peptide Design
Authors:
Rainier Barrett,
Andrew D. White
Abstract:
Often the development of novel functional peptides is not amenable to high throughput or purely computational screening methods. Peptides must be synthesized one at a time in a process that does not generate large amounts of data. One way this method can be improved is by ensuring that each experiment provides the best improvement in both peptide properties and predictive modeling accuracy. Here,…
▽ More
Often the development of novel functional peptides is not amenable to high throughput or purely computational screening methods. Peptides must be synthesized one at a time in a process that does not generate large amounts of data. One way this method can be improved is by ensuring that each experiment provides the best improvement in both peptide properties and predictive modeling accuracy. Here, we study the effectiveness of active learning, optimizing experiment order, and meta-learning, transferring knowledge between contexts, to reduce the number of experiments necessary to build a predictive model. We present a multi-task benchmark database of peptides designed to advance these methods for experimental design. Each task is binary classification of peptides represented as a sequence string. We find neither active learning method tested to be better than random choice. The meta-learning method Reptile was found to improve average accuracy across datasets. Combining meta-learning with active learning offers inconsistent benefits.
△ Less
Submitted 10 December, 2020; v1 submitted 20 November, 2019;
originally announced November 2019.
-
Classifying Antimicrobial and Multifunctional Peptides with Bayesian Network Models
Authors:
Rainier Barrett,
Shaoyi Jiang,
Andrew D White
Abstract:
Bayesian network models are finding success in characterizing enzyme-catalyzed reactions, slow conformational changes, predicting enzyme inhibition, and genomics. In this work, we apply them to statistical modeling of peptides by simultaneously identifying amino acid sequence motifs and using a motif-based model to clarify the role motifs may play in antimicrobial activity. We construct models of…
▽ More
Bayesian network models are finding success in characterizing enzyme-catalyzed reactions, slow conformational changes, predicting enzyme inhibition, and genomics. In this work, we apply them to statistical modeling of peptides by simultaneously identifying amino acid sequence motifs and using a motif-based model to clarify the role motifs may play in antimicrobial activity. We construct models of increasing sophistication, demonstrating how chemical knowledge of a peptide system may be embedded without requiring new derivation of model fitting equations after changing model structure. These models are used to construct classifiers with good performance (94% accuracy, Matthews correlation coefficient of 0.87) at predicting antimicrobial activity in peptides, while at the same time being built of interpretable parameters. We demonstrate use of these models to identify peptides that are potentially both antimicrobial and antifouling, and show that the background distribution of amino acids could play a greater role in activity than sequence motifs do. This provides an advancement in the type of peptide activity modeling that can be done and the ease in which models can be constructed.
△ Less
Submitted 17 April, 2018;
originally announced April 2018.
